In an exclusive conversation with Deccan Chronicle, Dr. G Vikram Kumar sheds light on the complexities of hemophilia, its impact on patients’ lives, and the recent breakthroughs in the ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.